- Home
- BLSM vs TRXB Comparison
BLSM vs TRXB Comparison
Compare BLSM & TRXB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLSM | TRXB |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.4M | 388.6M |
| IPO Year | 2026 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BLSM | TRXB |
|---|---|---|
| Price | $15.15 | $13.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $35.40 | $29.25 |
| AVG Volume (30 Days) | ★ 141.0K | 86.0K |
| Earning Date | 11-19-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.02 | $12.50 |
| 52 Week High | $27.99 | $16.56 |
Technical Indicators
Market Signals| Indicator | BLSM | TRXB |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 45.41 |
| Support Level | $12.93 | $13.01 |
| Resistance Level | $17.53 | $16.56 |
| Average True Range (ATR) | 1.73 | 1.22 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 53.30 | 22.66 |
Price Performance
Historical ComparisonAbout BLSM BlossomHill Therapeutics Inc. Common Stock
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.